Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls

European Journal of Clinical Pharmacology

Volumn 62, Issue 12, 2006, Pages 1041-1048

  Petersen, Maria Skaalum ^a   Halling, Jónrit ^a   Damkier, Per ^a,b   Nielsen, Flemming ^a   Grandjean, Philippe ^a,d   Weihe, Pál ^a,c   Brøsen, Kim ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c FAROESE HOSPITAL SYSTEM   (Faroe Islands)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Caffeine; Caffeine metabolic ratio; CYP1A2; Faroe Islands; N3 demethylation; Polychlorinated biphenyls

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 1,7 DIMETHYLURIC ACID; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; CAFFEINE; CYTOCHROME P450 1A2; DIOXIN; ORAL CONTRACEPTIVE AGENT; POLYCHLORINATED BIPHENYL;

ADULT; ARTICLE; BLOOD LEVEL; CALCULATION; CONTROLLED STUDY; DEMETHYLATION; DRUG DETERMINATION; DRUG METABOLISM; DRUG USE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC RATE; METABOLITE; MULTIPLE REGRESSION; ORAL CONTRACEPTION; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOMETRY; CAFFEINE; COHORT STUDIES; CYTOCHROME P-450 CYP1A2; ENVIRONMENTAL POLLUTANTS; FEMALE; GENOTYPE; HUMANS; MALE; METHYLATION; MIDDLE AGED; POLYCHLORINATED BIPHENYLS; SEX FACTORS; SMOKING; URACIL; URIC ACID; XANTHINES;

EID: 33751245888     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0205-0     Document Type: Article

References (46)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
2. Wolf CR, Smith G (1999) Pharmacogenetics. Br Med Bull 55:366-386
3. Brøsen K (1995) Drug interactions and the cytochrome P450 system. Clin Pharmacokinet 29:20-25
4. Shimada T, Inoue K, Suzuki Y, Kawai T et al (2002) Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis 23:1199-1207
5. Shimada T, Iwasaki M, Martin MV, Guengerich FP (1989) Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002. Cancer Res 49 (12):3218-3228
6. Eaton DL, Gallagher EP, Bammler TK, Kunze KL (1995) Role of cytochrome CYP1A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5(5):259-274, Review
7. Abernethy DR, Todd EL (1985) Impairment of caffeine clearence by chromic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 28:425-428
8. Rietveld EC, Broekman MM, Houben JJ, Eskes TK, van Rossum JM (1984) Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids. Eur J Clin Pharmacol 26(3):371-373
9. Kalow W, Tang B-K (1991) Caffeine as a metabolic probe: exploration of enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44-48
10. Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M (1998) A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 53:361-367
11. Parsons WD, Neims AH (1978) Effect of smoking on caffeine clearance. Clin Pharmacol Ther 24(1):40-45
12. Butler MA, Lang NP, Young JF, Caporaso NE et al (1992) Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2(3):116-127
13. Rasmussen BB, Brix TH, Kyvik KO, Brøsen K (2002) The interindividuel differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharamacogenetics 12:473-478
14. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421
15. Aklillu E, Carrillo JA, Makonnen E, Hellman K et al (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64 (3):659-669
16. Sachse C, Bhambra U, Smith G, Lightfoot TJ et al (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55(1):68-76
17. Huang J, Guo W, Lai M, Guo Y, Lambert GH (1999) Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Am Soc Pharmacol Exp Ther 27:98-101
18. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 59-flanking region of human CYP1A2 inducibility in humans. J Biochem (Tokyo) 125:803-808
19. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
20. Pavanello S, Puliero A, Lupi S, Gregorio P, Clonfero E (2005) Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 587:59-66
21. http://www.imm.ki.se/CYPalleles/CYP1A2.htm
22. Safe SH (1994) Polychlorinated Biphenyls (PCB): environmental impact, biochemical and toxic responses, and implication for risk assessment. Crit Rev Toxicol 24:87-149
23. Lake BG, Charzat C, Tredger JM, Renwich AB, Beamand JA, Prince RJ (1996) Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices. Xenobiotica 26:297-306
24. Fitzgerald EF, Hwang S, Lambert G, Gomez M, Tarbell A (2005) PCB exposure and in vivo CYP1A2 activity among native Americans. Environ Health Perspect 113:1-6
25. Halperin W, Kalow W, Sweeney MH, Tang BK et al (1995) Induction of P-450 in workers exposed to dioxin. Occup Environ Med 52:86-91
26. Abraham K, Geusau A, Tosun Y, Helge H, Bauer S, Brockmoller J (2002) Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome CYP1A2 induction. Clin Pharmacol Ther 72(2): 163-174
27. Lambert GH, Schoeller DA, Humphrey HE, Kotake AN et al (1990) The caffeine breath test and caffeine urinary metabolite ratios in the Michigan cohort exposed to polybrominated biphenyls: a preliminary study. Environ Health Perspect 89:175-181
28. http://www.atsdr.cdc.gov/toxprofiles/tp17.html
29. Bloch D, Desportes G, Hoydal K, Jean P (1990) Pilot whaling in the Faroe Islands, July 1986-July 1988. North Atlantic Studies 2:36-44
30. Grandjean P, Weihe P, Burse VW, Needham LL et al (2001) Neurobehavioral deficits associated with PCB in 7-year-old children prenatally exposed to seafood neurotoxicants. Neurotoxicol Teratol 23(4):305-317
31. Longnecker MP, Wolff MS, Gladen BC, Brock JW, Grandjean P et al (2003) Comparison of polychlorinated biphenyl (PCB) levels across studies of human neurodevelopment. Environ Health Perspect 111:65-70
32. Deutch B, Hansen JC (eds) (2003) AMAP Greenland and the Faroe Islands 1997-2001. Danish Environmental Protection Agency, Copenhagen
33. Steuerwald U, Weihe P, Jørgensen PJ, Bjerve K, Brock J et al (2000) Maternal seafood diet, methylmercury exposure, and neonatal neurological function. J Pediatr 136:599-605
34. Moysich KB, Ambrosone CB, Mendola P, Kostyniak PJ et al (2002) Exposures associated with serum organochlorine levels among postmenopausal women from Western New York state. Am J Ind Med 41:102-110
35. Campbell ME, Spielberg SP, Kalow W (1987) A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42:157-165
36. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P et al (2005) Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 61 (7):491-497
37. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62(4):365-376
38. Rasmussen BB, Brøsen K (1996) Determination of urinary metabolites of caffeine for the assessment of cytochrome CYP1A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 18:254-262
39. Heilmann C, Grandjean P, Weihe P, Nielsen F, Budtz-Jørgensen E (2006) Reduced antibody responses to vaccinations in children exposed to polychlorinated biphenyls. PLoS Medicine 3(8): e311. DOI 10.1371/journal.pmed. 0030311
40. Grandjean P, Weihe P, Needham LL, Burse VW et al (1995) Effect of a seafood diet on mercury, selenium, arsenic, and PCBs and other organochlorines in human milk. Environ Res 71:29-38
41. Ahlborg UG, Becking GC, Birnbaum LS, Brouwer A et al (1994) Toxic equivalency factors for dioxin-like PCBs. Chemosphere 28:1049-1067
42. Kalow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53(5):503-514, Review
43. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW (1995) Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 39(1):65-69
44. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279, Nov
45. Bae SY, Choi SK, Kim KR, Park CS et al (2006) Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 97:774-779
46. National Toxicology Program (2006) NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies). Natl Toxicol Program Tech Rep Ser 521:4-232